Dr. Reddy's Laboratories has entered an exclusive collaboration with Takeda Biopharmaceuticals India to distribute and market the Qdenga dengue vaccine in India's private market. The vaccine, approved by the Central Drugs Standard Control Organization in July 2026 for people aged 4-60 years, is expected to become available during the first half of 2027. The agreement involves no upfront consideration or milestone payments, limiting immediate financial commitments while expanding Dr. Reddy's vaccine portfolio.
Dr. Reddy's Laboratories Secures Exclusive India Private-Market Rights for Qdenga Dengue Vaccine
Launch expected in the first half of 2027.
No upfront consideration or milestone payments under the collaboration.
Reader Takeaway: Expands vaccine portfolio with limited upfront cost, but commercial success depends on private-market adoption.
What just happened
Dr. Reddy's Laboratories has signed an exclusive collaboration with Takeda Biopharmaceuticals India Private Limited to distribute and market Qdenga, a dengue vaccine, in India's private healthcare market.
Qdenga received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) in July 2026. It is approved for individuals between 4 and 60 years of age.
Under the agreement, Dr. Reddy's will handle distribution and marketing for the private market, while Takeda will retain rights in the public market and continue to manufacture and import the vaccine.
The commercial launch is expected during the first half of 2027.
Why this matters
The collaboration strengthens Dr. Reddy's presence in India's vaccine segment by adding an approved dengue vaccine to its portfolio.
The agreement also provides access to a product targeting a disease that continues to have a significant public health impact in India.
What changes now
The filing confirms that Dr. Reddy's will become the exclusive private-market commercial partner for Qdenga in India.
The structure of the agreement also limits immediate financial commitments because there are no upfront payments or milestone-based payments associated with the collaboration.
Takeda will continue to manage manufacturing, imports and public-market commercialisation.
Risks to watch
Investors should monitor:
- Commercial launch during the first half of 2027.
- Adoption in India's private healthcare market.
- Sales contribution from the vaccine after launch.
- Expansion of Dr. Reddy's vaccines business through similar partnerships.
What to track next
The next milestones include product availability during H1 2027, rollout across private healthcare channels and updates on commercial performance after launch.